Gallant Secures $18 Million in Funding for Revolutionary Stem Cell Therapy for Pets
In a groundbreaking move for veterinary medicine, San Diego-based startup Gallant has recently announced $18 million in funding to develop the first FDA-approved ready-to-use stem cell therapy for pets. This innovative treatment could potentially revolutionize the way we care for our beloved furry companions.
Although stem cell research has been a topic of interest in human medicine for decades, the field is still considered experimental in the realm of veterinary care. Gallant, a seven-year-old company, is focusing its efforts on addressing Feline Chronic Gingivostomatitis (FCGS), a painful mouth condition in cats. The company aims to obtain FDA approval for this treatment by early 2026.
Initial studies have shown promising results in the use of stem cell therapy for conditions such as arthritis in dogs, demonstrating improvements in pain relief and mobility that can last up to two years. However, when it comes to treating kidney disease in cats, the outcomes have been more varied.
What sets Gallant apart is its approach to convenience. While traditional stem cell therapies require cells to be harvested from either the patient or compatible donors, Gallant’s therapy utilizes ready-to-use cells from donor animals, even if they are of a different species.
The recent funding round, led by Digitalis Ventures and NovaQuest Capital Management, reflects the potential that investors see in Gallant’s innovative approach. NovaQuest has previously invested in the first FDA-approved human stem cell therapy.
Gallant’s journey is marked by an intriguing backstory. Founded by Aaron Hirschhorn, who tragically passed away in 2021, the company is now under the leadership of Linda Black, who has been with Gallant since its early days. Hirschhorn, known for selling DogVacay to Rover, brought his entrepreneurial spirit to Gallant, which has now raised a total of $44 million from investors.
